AMGEN Inc
NASDAQ: AMGN
$294.00
-$0.53 (-0.2%)
Closing Price on November 25, 2024
AMGN Articles
Though Amgen reported better-than-expected third-quarter results on Thursday, shares sank early Friday.
Published:
Last Updated:
Biotech giant Amgen is scheduled to release its third-quarter financial results after the markets close on Thursday.
Published:
Last Updated:
The October 14 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Last Updated:
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
Published:
Last Updated:
Americans generally would like to spend less money on health care. One way that this can be and will be accomplished is through the continued use and expanded use of generic drugs.
Published:
Last Updated:
These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.
Published:
Last Updated:
If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a stock implosion down the road.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.
Published:
Last Updated:
In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster Humira being approved took the backseat to many other things.
Published:
Last Updated:
An RBC report noted that although headline issues such as the Federal Reserve and the election are increasing volatility, four top biotech companies may be a solid play now.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous report, and short interest decreased for most of these selected biotech stocks.
Published:
Last Updated:
The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across these selected biotech stocks.
Published:
Last Updated:
The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech stocks.
Published:
Last Updated:
According to one analyst, Advaxis shares could still easily more than double, even after news broke that biotech giant Amgen will become its partner.
Published:
Last Updated:
Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there was little to no mention of drug pricing.
Published:
Last Updated: